Advertisements

Olynth 0.025%

Quick links to important sections

Olynth 0.025%

Advertisements

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Olynth 0.025%

Property Description
Active ingredient Xylometazoline hydrochloride
Form Aqueous Nasal Solution / Nasal Drops (0.025% strength)
Pharmacological class Sympathomimetic Agent / Nasal Decongestant
Common use Relieving a blocked or stuffy nose
Origin Synthetic (Imidazoline derivative)

The Identity and Classification of Olynth 0.025%

Olynth 0.025% is a specific formulation of a nasal decongestant medication applied topically to the nose. The drug is classified as a sympathomimetic agent, specifically an alpha-adrenergic agonist. This classification is clinically recognized for its direct action on blood vessels.

The medicine is a synthetic, single-ingredient product that utilizes Xylometazoline hydrochloride as its sole active pharmaceutical ingredient (API). Xylometazoline is chemically recognized as an imidazoline derivative, a class of synthetic organic compounds known for inducing localized vasoconstriction. The specific 0.025% concentration of this nasal solution is distinctly formulated for the sensitive pediatric target audience, setting it apart from the standard 0.05% or 0.1% solutions intended for older children and adults.


Olynth 0.025%: Formulation and General Purpose

The medication is prepared as an aqueous solution designed for nasal administration via nasal drops. This liquid, water-based formulation allows for direct, localized delivery of the active ingredient to the nasal mucosa.

The general therapeutic purpose of Olynth 0.025% is the immediate and temporary relief of airway obstruction, a typical scenario being a stuffy nose associated with the common cold. This benefit is achieved because the Xylometazoline active ingredient causes localized vasoconstriction—the narrowing of tiny blood vessels in the nasal lining. This action physically shrinks the swollen nasal tissues, thereby reducing the associated tissue hyperemia and swelling (edema). This vasoconstrictive principle functions to clear the nasal airways. This highly localized topical delivery focuses the medication's effect precisely where it is needed.

Advertisements

What side effects are possible with Olynth 0.025%?

Official Safety Profile of Xylometazoline 0.025%

The safety profile of Xylometazoline, the active ingredient in Olynth 0.025%, is based on the classification of adverse reactions by frequency and the organ systems they affect, as documented in official government regulatory sources.

Adverse Reaction Classification

Side effects are categorized by frequency, following standard regulatory conventions (Common, Uncommon, Rare):

Frequency Category Associated System-Organ Classes Examples of Documented Reactions
Common Respiratory, Thoracic and Mediastinal Disorders Nasal discomfort, burning sensation in the nose and throat, dry nasal mucosa, sneezing.
Uncommon Immune System Disorders Hypersensitivity reactions (e.g., rash, pruritus).
Rare Cardiac Disorders, Nervous System Disorders Palpitations, tachycardia (increased heart rate), hypertension (increased blood pressure), headache.

Safety Considerations and Restrictions

Official labeling defines specific safety limitations. A pattern noted in regulatory documents is the risk of Rebound Congestion (Rhinitis medicamentosa), which is explicitly associated with prolonged or excessive use beyond the recommended duration. This effect involves increased swelling of the nasal mucous membranes after the medicine wears off.

Formal Contraindications represent absolute safety restrictions where the medicine must not be used, including patients with atrophic rhinitis or Rhinitis sicca, closed-angle glaucoma, and those who have undergone specific brain surgeries. Additionally, use is restricted in patients concurrently taking, or who have recently taken, Monoamine Oxidase Inhibitors (MAOIs) due to the potential for a hypertensive crisis.

Caution is also advised for individuals with pre-existing conditions such as severe cardiovascular disorders, hyperthyroidism, Phaeochromocytoma, and Long QT syndrome, as the systemic absorption of the vasoconstrictive agent may pose a risk.

Advertisements

Overdose and Emergency Response

Overdose from Olynth 0.025% (Xylometazoline hydrochloride) is officially documented following accidental ingestion or excessive topical administration, with regulatory labeling noting that small children are more sensitive to toxicity than adults. This is a significant consideration, particularly for children 5 years of age and younger.

Overdose can result in severe life-threatening consequences due to the systemic absorption of the active agent. Documented manifestations include effects on the Central Nervous System (CNS) such as severe dizziness, lethargy, stupor, convulsions, and progression to coma. Cardiovascular effects may involve bradycardia (slowed pulse), significant fluctuations in blood pressure (hypertension followed by hypotension), and respiratory depression.

In the event of an overdose, regulatory authorities mandate that individuals seek emergency medical care immediately or call a poison control centre or doctor immediately, even if signs are not yet apparent. The documented emergency response is focused on providing urgent symptomatic and supportive treatment under medical supervision. Hospital observation, potentially for several hours, may be required. Official labeling notes that no specific antidote is known for Xylometazoline overdose.

Advertisements

Therapeutic Uses of Olynth 0.025%

What Olynth 0.025% Treats: Main Uses and Benefits

The 0.025% concentration of Olynth is commonly used to help provide short-term symptomatic support, primarily targeting symptoms that create noticeable physiological strain in its target pediatric audience.

The core therapeutic purpose of Xylometazoline is the temporary symptomatic management of nasal congestion. The medication is commonly applied across conditions presenting with acute episodes, including the common cold (acute rhinitis), allergic rhinitis (hay fever), and as supportive relief for sinusitis and otitis media. These uses are relevant when supportive symptom management is appropriate for conditions marked by periods of heightened nasal mucosal swelling.

“The intended focus of this symptomatic approach is functional: it assists with maintaining stability by easing the overall symptom load.”

By addressing the severe nasal blockage, the product contributes to improved day-to-day comfort during symptomatic periods. This symptomatic assistance is highly relevant for young children, as it supports crucial activities like sleeping and feeding/drinking, which are often disrupted when symptoms become momentarily overwhelming.

Quick Fact: Relief for Nasal Airway Obstruction
Olynth 0.025% is used for managing the congestion that interferes with daily functioning, supporting easier breathing during episodes of acute or episodic changes.

Regulatory References

  1. Dutch Medicines Evaluation Board Public Assessment Report
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Olynth 0.025%

The eligibility for Olynth 0.025% (Xylometazoline hydrochloride) is strictly defined by regulatory documents, focusing primarily on age and specific clinical exclusions.

Approved and Prohibited Age Groups

The 0.025% concentration is approved for use exclusively in children aged 2 to 6 years. The medicine is contraindicated and must not be used in infants and children under 2 years of age.

Absolute Contraindications

Use is officially prohibited in patients with known hypersensitivity to the active ingredient or excipients, rhinitis sicca (dry nasal inflammation), or specific surgical history, such as transsphenoidal hypophysectomy or other procedures that expose the dura mater. Patients with narrow-angle glaucoma or Phaeochromocytoma must also not use this medicine.

Restricted Use and Special Caution

Use requires special caution and medical oversight for individuals with certain pre-existing conditions, including hypertension, severe cardiovascular disease, diabetes mellitus, hyperthyroidism, or prostatic hypertrophy. The medicine is also contraindicated in patients who are currently taking or have taken MAO inhibitors within the last two weeks. Use is not recommended for women who are pregnant or breastfeeding.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Olynth 0.025% (Xylometazoline hydrochloride) is defined primarily by pharmacodynamic effects related to its classification as a sympathomimetic agent.


Documented Pharmacodynamic Interactions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated, including within 14 days of discontinuing MAOI treatment. This restriction is due to the documented risk of severe blood pressure elevation or a hypertensive crisis resulting from pressor reinforcement. Similarly, the use of Xylometazoline with Tri-cyclic or Tetra-cyclic Antidepressants is restricted as the combination can intensify the sympathomimetic effect, which may lead to an increase in blood pressure.

Interaction-Related Constraints

Xylometazoline may also result in the Antagonism of Antihypertensive Therapy by blocking the hypotensive effects of certain medicines used to lower blood pressure, such as beta-blockers. For this reason, co-administration with other Sympathomimetic Decongestants is restricted due to the potential for additive cardiovascular effects.

Population-Specific Caution

Official labeling includes a caution for patients with Long QT syndrome, who may face an increased risk of serious ventricular arrhythmias due to the potential systemic effects of the sympathomimetic agent.

Advertisements

Mechanism of Action

Alpha-Adrenergic Receptor Engagement and Vasoconstriction

The core mechanism of Xylometazoline is its action as a direct alpha-adrenergic agonist. This means the molecule targets and activates the alpha1 and alpha2 receptors found on the vascular smooth muscle within the nasal lining. This receptor activation initiates an intracellular signaling cascade that forces the small blood vessels (arterioles and venules) to contract, resulting in localized sympathetic vasoconstriction.

Physiological Cascade: Tissue Shrinkage and Airway Widening

The resulting vasoconstriction sharply limits the flow and volume of blood (hyperemia) in the nasal submucosa, thereby reducing the hydrostatic pressure and limiting fluid leakage into the tissue space. This physiological cascade directly produces detumescence (shrinking) of the swollen mucosal tissues, which physically widens the internal nasal airway. The mechanism is entirely physical-vasomotor, not anti-inflammatory.

Mechanism Limitations: Tachyphylaxis and Rebound

The response of this mechanism is constrained by the phenomenon of tachyphylaxis, wherein continuous exposure to Xylometazoline causes the target alpha-receptors to become rapidly desensitized or downregulated. The failure of receptor responsiveness can lead to a compensatory, excessive vasodilation and exacerbation of mucosal swelling, which is the mechanism underlying Rhinitis medicamentosa (paradoxical mucosal swelling) associated with prolonged use.

Advertisements

Dosage and Administration Information

How to Use Olynth 0.025% — Official Administration Guidelines

Olynth 0.025% is a specific, lower concentration of Xylometazoline hydrochloride solution, with official usage protocols governed by its intended application and target population.


Administration Scope

The medicine is designed for topical administration, delivered as nasal drops. The 0.025% strength is explicitly indicated for use in children aged 2 to 6 years.

Feature Official Instruction
Route of administration Topical (Nasal)
Dosing schedule One to two drops into each nostril per application.
Age-group administration rules Intended for children 2 to 6 years of age.
Frequency pattern Up to three times daily (2 to 3 times per 24 hours), with doses spaced 8 to 10 hours apart.
Course Duration Limit Use is strictly limited to not more than 7 consecutive days

Procedural and Contextual Constraints

The usage protocol emphasizes control and hygiene. Administration of the drops should be supervised by an adult for the young pediatric patient to ensure accurate drop volume and correct technique.

The label-based instruction is to clear the nose (e.g., blow the nose gently) before application. The final dose of the day is recommended to be taken shortly before retiring to bed to support nighttime comfort. Critically, the product is intended for short-term use only; if symptoms do not improve after the maximum recommended duration, the official use protocol directs cessation. The container must be used by only one person to prevent the spread of infection.

Advertisements

Recent Clinical Evidence

Olynth 0.025%: Recent Clinical Evidence

This overview describes the research landscape for the active ingredient in Olynth 0.025%, focusing on the types of clinical studies performed, the patient groups examined, and the primary outcomes that research has explored, without offering any clinical advice or interpretation of results.


Evidence Base for Acute Nasal Congestion (The Common Cold)

Research into this compound's use for symptoms related to the common cold primarily relies on randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time and applied in trials assessing short-term or episodic symptom patterns. The studies were designed to measure changes in objective airflow through the nose, such as Nasal Conductance, alongside patient-reported subjective assessments of acute congestion symptoms.

It is important to note that many of the large, comparative RCTs that defined the parameters for studying decongestant activity used higher concentrations, such as the 0.1% or 0.05% solutions, often in adult populations. The evidence base for the specific lower 0.025% dose in children relies on applying the findings from studies of higher concentrations, as there are fewer comparative trials dedicated solely to that strength.

Studies Focusing on the Pediatric 0.025% Concentration

The 0.025% concentration was evaluated in research contexts involving its specific pediatric target audience. Research for this compound in its pediatric target audience primarily used observational studies and retrospective cohort studies rather than large-scale RCTs, particularly when examining use in the youngest populations. For example, the compound was observed in specialized clinical settings, such as retrospective studies focusing on hospitalized infants under two years of age receiving the 0.025% solution.

Understanding Follow-up Duration and Long-Term Data

The vast majority of clinical research conducted during periods of increased symptom activity was designed for research exploring brief symptomatic changes, typically assessing responses over defined time intervals of seven days or less. Research findings describe group patterns, and do not provide context for individual predictions or response over longer periods. Long-term effects are not fully established because the follow-up durations were limited in design.

Current Evidence Gaps and Areas of Uncertainty

A review of the research highlights what is known and what is still uncertain about this compound. One key limitation is that evidence quality varies across studies, particularly when moving from the high-level RCTs for higher concentrations to the specialized retrospective data for the 0.025% infant dose. These research gaps indicate areas where further study could provide additional information about outcomes in the specific pediatric population.

Key Studies & References

  1. Public Assessment Report (PAR) for Xylometazoline Hydrochloride 0.05% and 0.1% Nasal Spray
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Olynth 0.025% (FAQ)


Q: Is Olynth 0.025% a steroid or an antibiotic nasal spray?

Official classification shows that Olynth 0.025% is a sympathomimetic agent, not a steroid or an antibiotic. The medicine is designed to cause physical vasoconstriction, which is the narrowing of tiny blood vessels in the nasal lining. Its action is entirely physical-vasomotor and does not involve anti-inflammatory or antibacterial mechanisms.


Q: What is the meaning of the 0.025% concentration in the Olynth name?

The 0.025% concentration is specifically formulated for the sensitive pediatric target audience, which includes children aged 2 to 6 years. This low concentration contains a reduced amount of the active ingredient compared to solutions intended for older children or adults. This formulation is used to help limit the potential for the medicine's absorption into the bloodstream.


Q: Is there a risk of physical dependence on Olynth 0.025%?

Official labeling includes warnings about a condition called Rebound Congestion (Rhinitis medicamentosa), which is associated with prolonged or excessive use beyond the recommended duration. This condition causes the nasal swelling to worsen after the medicine wears off, potentially leading to increased need for the drug to clear the nose.


Q: What is the difference between Olynth 0.025% and a simple saline nasal spray?

The key difference lies in the mechanism of action. Olynth 0.025% is a medication that actively shrinks swollen tissue by causing vasoconstriction—the narrowing of tiny blood vessels in the nose. In contrast, a simple saline spray or rinse contains no active drug and works solely by moisturizing or flushing the nasal passages.


Q: Does Olynth 0.025% interact with common over-the-counter cold or flu medications?

Official product information restricts the co-administration of Olynth 0.025% with other Sympathomimetic Decongestants. This restriction is in place because using both together may lead to an additive effect on the heart and blood pressure. This restriction means individuals must be aware of the active ingredients in any other cold or flu medicines being used.


Q: Why do official product information sheets warn about potential systemic effects from a nasal spray?

The warning for potential systemic effects exists because the active ingredient can be absorbed into the bloodstream, even when applied topically to the nose. Official documents indicate that in rare instances, this absorption may lead to effects outside the nasal cavity, such as elevated blood pressure (hypertension) or an increased heart rate (tachycardia).


Q: What does the term 'sympathomimetic' mean in relation to the action of Olynth 0.025%?

The classification 'sympathomimetic' means that the active ingredient acts by mimicking the effects of certain natural substances, such as adrenaline, in the body's nervous system. When applied to the nose, this results in the rapid narrowing of blood vessels, which is called vasoconstriction.


Q: Why is correct technique important when applying a nasal spray like Olynth 0.025%?

Official administration protocols, which often require adult supervision for children, define the correct technique for ensuring the proper amount of medicine is delivered to the nasal lining. This technique also helps minimize the risk of swallowing an excessive amount of the solution. Accidental swallowing can increase the chance of systemic effects, as indicated in official warnings.


Q: What is the difference between Olynth 0.025% and nasal sprays containing corticosteroids?

Olynth 0.025% is a decongestant that physically shrinks swollen nasal tissue through vasoconstriction, and its action is explicitly not anti-inflammatory. Corticosteroids, by contrast, are a class of medicine whose primary purpose is to reduce inflammation and swelling over time.


Q: Is Olynth 0.025% generally used for congestion caused by a common cold or hay fever?

Official information indicates that Olynth 0.025% is used for the temporary relief of nasal congestion associated with the common cold. Its use is also indicated for relieving congestion symptoms related to hay fever or other respiratory allergies.


Q: How quickly does Olynth 0.025% usually start to relieve congestion?

Studies examining the effect of the active ingredient indicate that the relief of nasal congestion may start quickly. The median onset time of subjective relief has been reported to be around 1.7 minutes.


Q: How long does the congestion relief from Olynth 0.025% typically last?

The decongestant effect of the active ingredient is commonly described as long-lasting. Official product information indicates that the relief may remain active for a duration of up to 12 hours after administration.


Q: Does using Olynth 0.025% carry a risk of affecting sleep?

Official cautions state that use of sympathomimetic agents requires special consideration in individuals known to exhibit a strong reaction to this class of substances. In rare instances, a strong reaction may be evidenced by signs of overstimulation such as insomnia (difficulty sleeping).


Q: Is there a described interaction between Olynth 0.025% and alcohol?

Official drug interaction databases for the active ingredient in Olynth 0.025% have not found a documented interaction with alcohol (contained in alcoholic beverages).


Q: Does Olynth 0.025% cause drowsiness or affect a person's ability to concentrate?

The official safety profile lists headache as a common side effect of the medicine. Furthermore, dizziness is noted as a potential sign of a strong reaction to this class of medicines, and either of these effects may indirectly impact a person’s ability to concentrate.


Q: Is Olynth 0.025% suitable for relieving symptoms of a sinus infection (sinusitis)?

Xylometazoline, the active ingredient in Olynth 0.025%, is indicated for the temporary relief of nasal congestion. This includes congestion associated with conditions such as the common cold and sinusitis.


Q: Does Olynth 0.025% contain a preservative, and is that of concern to users?

The product often contains a preservative, such as benzalkonium chloride, as listed in the excipients section of the product information. Official labeling notes that this substance may cause irritation or swelling inside the nose, particularly if the product is used for a long time.


Q: Are there any warnings about changes in taste or smell after using this type of nasal spray?

Official warnings about the condition of rebound congestion (rhinitis medicamentosa) suggest a risk of worsening symptoms from prolonged or excessive use. Changes or loss of taste and smell have been linked to the development of this complication.


Q: Is it possible for Olynth 0.025% to be accidentally swallowed, and what are the effects?

The official overdose section addresses the effects of accidental ingestion of the solution. Potential effects include severe dizziness, headache, and a lowered body temperature. Furthermore, there may be changes in heart rate (increased or decreased) and increased blood pressure.


Q: Is Olynth 0.025% the same type of medicine as other nasal decongestants like oxymetazoline?

Olynth 0.025% (Xylometazoline) and Oxymetazoline are in the same pharmacological class, known as topical decongestants and alpha-adrenergic agonists. This means they work by similar mechanisms to relieve congestion. However, official drug classification confirms they are different chemical compounds.


Q: What are the signs of accidental overdose in children described in official sources?

In rare instances of accidental poisoning in children, official sources have described the signs as including an accelerated and irregular pulse and elevated blood pressure. Additionally, these signs may sometimes be accompanied by clouding of consciousness.

Advertisements

How should Olynth 0.025% be stored and disposed of?

Storage and Disposal of Olynth 0.025%

Storage Requirements

Olynth 0.025% (Xylometazoline hydrochloride) must be stored at controlled room temperature, typically below 25 C (77 F). It is essential to protect the solution from light and do not freeze the product to maintain its stability. The medication must always be kept in its original container with the cap tightly closed when not in use.

Stability and Child Safety

For hygiene and safety, the nasal solution has an in-use shelf-life and must be discarded 28 days (4 weeks) after first opening the bottle. Critically, keep this medicine out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Do not dispose of unused or expired Olynth 0.025% in wastewater or general household waste. The product must be managed as pharmaceutical waste, and its disposal should be completed in accordance with local regulatory requirements, often by returning it to a designated collection point or pharmacy.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Olynth 0.025% found in:

A-Z Index: